Back to Find a Doctor
Dr. Alan N. Gordon

Alan N. Gordon, MD, FACOG, FACS

I am a board-certified gynecologic oncologist in the Department of Gynecology and Obstetrics at Emory School of Medicine. My practice includes treatment of all the gynecologic malignancies but I have a special interest in ovarian cancer and gestational trophoblastic disease. I also take care of patients with benign gynecologic problems that require complex surgical procedures.


  • Gynecologic Oncology
  • Gynecology/Obstetrics

Board Certifications

  • ABMS Nuclear Medicine


  • Johns Hopkins Hospital


  • Emory

Education & Training

  • Medical School: Johns Hopkins University
  • Residency: Johns Hopkins Hospital

Honors & Awards

Willaford Ransom Leach Professor of Gynecology

ACOG Excellence in Teaching

Phi Beta Kappa


Gordon A, Rosenshein N, Parmley T, Bhagavan B: Benign cystic teratomas in post-menopausal women. Am J Obstet Gynecol 138:1120-1123, 1980.

Gordon AN, Lipton DJ, Woodruff JD: Dysgerminoma: Review of 158 cases from the Emil Novak Tumor Registry. Obstet Gynecol 58:497-504, 1981.

Gordon AN, Kavanagh JJ, Wharton JT, Rutledge FN, Obbens EA, Bodey GP: Successful treatment of leptomeningeal relapse of epithelial ovarian cancer. Gynecol Oncol 18:119-124, 1984.

Gordon AN, Gershenson DM, Copeland LJ, Saul PB, Kavanagh JJ, Edwards CL: High-risk metastatic gestational trophoblastic disease. Obstet Gynecol 65:550-556, 1985.

Gordon AN, Johnson JWC: Value of umbilical blood acid-base studies in fetal assessment. J Reprod Med 30:329-336, 1985.

Gordon AN, Kavanagh JJ, Gershenson DM, Saul PB, Copeland LJ, Stringer, CA: Cisplatinum, vinblastine and bleomycin combination therapy in resistant gestational trophoblastic disease. Cancer 58:1407-1410, 1986.

Kaufman RH, Bornstein J, Gordon A, Adam E, Kaplan AL, Adler-Storthz K: Detection of human papillomavirus DNA in advanced epithelial ovarian carcinoma. Gynecol Oncol 27:340-350, 1987.

Dieste MC, Lynch GR, Gordon AN, Estrada R, Lane M: Malignant fibrous histiocytoma of the broad ligament: A case report and literature review. Gynecol Oncol 28:225-229, 1987.

Pruett KM, Gordon AN, Estrada R, Lynch GR: Small cell carcinoma of the ovary: An Aggressive epithelial cancer occurring in young patients. Gynecol Oncol 29: 365-369, 1988.

Reeves KO, Young RL, Gordon AN, Thomas Jr SJ, Redwine WA, Edward GR: Sigmoidovaginal fistula secondary to diverticular disease. J Reprod Med 33:313-316, 1988.

Kirshon B, Young R, Gordon AN: Conservative management of abdominal gunshot in pregnancy. Am J Perinatol 5:232-233, 1988.

Gordon AN, Lynch GR: Multi-agent chemotherapy in combination with fractionated radiation therapy for advanced carcinoma of the cervix: Acute toxicity. Eur J Gynaec Oncol 9:351-354, 1988.

VanSickle M, Gordon AN, Lynch GR: Chemotherapeutic response consolidated with radiation in adenocarcinoma of the cervix with para-aortic nodal metastasis. Am J Gynecol Health 5:12-15, 1989.

Levitan Z, Gordon AN, Kaplan AL, Kaufman RH: Primary malignant melanoma of the vagina: Report of four cases and review of the literature. Gynecol Oncol 33:85-90, 1989.

Gordon AN, Gershenson DM, Copeland LJ, Stringer CA, Morris M, Wharton JT: High-risk metastatic gestational trophoblastic disease: Further stratification into two clinical entities. Gynecol Oncol 34:54-56, 1989.

Gordon AN, Fleischer AC, Dudley BS, Drolshagan LF, Kalemaris GC, Partain CL, Jones HW, Burnett LS: Preoperative assessment of myometrial invasion of endometrial adenocarcinoma by sonography (US) and magnetic resonance imaging (MRI). Gynecol Oncol 34:175-179, 1989.

Gordon AN, Jensen R, Jones HW: Squamous carcinoma of the cervix complicating pregnancy; recurrence in the episiotomy following vaginal delivery. Obstet Gynecol 73:850-852, 1989.

Fleischer AC, Gordon AN, Entman SS: Transvaginal sonography of palpable adnexal masses: Does it add specificity? Ultrasound Med Biol 15: 529-533, 1989.

Gordon AN, Martens M, LaPread Y, Faro S: Response of lower genital tract flora to external pelvic irradiation. Gynecol Oncol 35:233-235, 1989.

Gordon AN, Bornstein J, Kaufman RH, Estrada RG, Adams E, Adler-Storthz K: Human papillomavirus associated with adenocarcinoma and adenosquamous carcinoma of the cervix: Analysis by in situ hybridization. Gynecol Oncol 35:345-348, 1989.

Gordon AN, Montag T: Sarcoma botryoides of the cervix: Excision followed by adjuvant chemotherapy for preservation of reproductive function. Gynecol Oncol 36:119-124, 1990.

Levitan Z, Kaplan A, Gordon AN: Survival following malignant pericardial effusion and cardiac tamponade in advanced ovarian cancer. South Med J 83:241-242, 1990.

Gordon AN, Fleischer AC, Reed GW: Depth of myometrial invasion in endometrial cancer: Pre-operative assessment by transvaginal sonography. Gynecol Oncol 39:321-327, 1990.

Stringer CA, Gershenson DM, Burke TS, Edwards CL, Gordon AN, Wharton JT: Adjuvant chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (PAC) for early-stage high-risk endometrial cancer: A preliminary analysis. Gynecol Oncol 38:305-308, 1990.

Fleischer AC, McKee MS, Gordon AN, Page DL, Kepple DM, Worrell JA, Jones III HW, Burnett LS, James Jr AE: Transvaginal Sonography of postmenopausal ovaries with pathologic correlation. J Ultrasound Med 9:637-644, 1990.

Gordon AN, Stringer CA, Matthews CM, Willis DL and Nemunaitis J. Phase I dose escalation of Paclitaxel in patients with advanced ovarian cancer receiving Cisplatin: Rapid development of neurotoxicity is dose-limiting. J Clin Oncol 15:1965-1973, 1997.

Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmstrom H, Coleman R, Fields SC and Heron JF. Topotecan versus Paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193, 1997.

Bookman MA, Malmstrom H, Bolis G, Gordon A, Lissoni A, Krebs JB, Fields SZ. Topotecan for the Treatment of Advanced Epithelial Ovarian Cancer: An Open-Label Phase II Study in Patients Treated After Prior Chemotherapy Containing Cisplatin or Carboplatin and Paclitaxel. J Clin Oncol 16:3345-3352, 1998.

Gordon AN, Hancock KC, Matthews CM, Stringer CA, Boston J, Neumanitis J. A phase I/II dose escalation study of carboplatin in the treatment of newly diagnosed patients with advanced ovarian cancer receiving paclitaxel. Am J Clin Oncol 22:601-605,1999.

Gordon AN, Granai CO, Rose P, Hainsworth, Lopez A, Weissman C, Rosales R, Sharpington T. Phase II Study of Stealth® Liposomal Doxorubicin (Doxil®) in Platinum and Paclitaxel Refractory Epithelial Ovarian Cancer. J Clin Oncol 18:3093-3100,2000.

Gore M, Huinink WtB, Carmichael J, Gordon A, Davidson N, Coleman R, Spanczynski M, Heron JF, Bolis G, Malmstrom H, Malfetano J, Scarabelli C, Vennin P, Ross G, Fields SZ. Clinical evidence for topotecan – paclitaxel noncross-resistance in ovarian cancer. J Clin Oncol 19:1893-1900,2001.

Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin versus Topotecan. J Clin Oncol 19:3312-3322, 2001.

Zou W, Machelon V, Coulomb-L’Hermin A, Borvak J, Nome F, Isaeva T, Wei S, Krzysiek R, Durand-Gasselin I, Gordon A, Pustilnik T, Curiel DT, Galanaud P, Capron F, Emilie D, Curiel TJ. Stomal derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 7:1339-1346, 2001.

Gordon AN, Hancock KC, Matthews CM, Messing M, Stringer CA, Doherty MG, Teneriello M. Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer. Gynecol Oncol 85:129-135, 2002.

Smith DH, Adams JR, Johnston SRD, Gordon A, Drummond MF, Bennett CL. A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK. Annals Oncology 13: 1590-1597, 2002.

Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, Odile D, Burow M, Gordon A, Dhurandhar N, Myers L, Berggren R, Hemminki A, Alvarez RD, Emilie D, Curiel DT, Chen L and Zou W. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 9:5:562-567, 2003.

Chan SY, Gordon AN, Coleman RE, Hall JB, Berger MS, Sherman ML, Eten CB, Finkler NJ. A phase II study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian cancinoma. Cancer Immunology Immunotherapy 52:243-8,2003.

Gordon AN, Schultes BC, Gallion H, Edwards R, Whiteside TL, Cermak JM, Nicodemus CF. CA125- and Tumor-Specific T-Cell Responses Correlate with Prolonged Survival in Oregovomab- treated Recurrent Ovarian Cancer Patients. Gynecol Oncol 94:340-351, 2004.

Gordon AN, Asmar L, Messing MJ, Street DG, Pippitt CH, Bailey CL, Savage J, Young JA. Phase II Study of Sequential Doublets: Topotecan and Carboplatin, Followed by Paclitaxel and Carboplatin, in Patients With Newly Diagnosed Advanced Ovarian Cancer. Gynecol Oncol 94:533-9, 2004.

Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942-9, 2004.

Gordon AN, Tonda M, Sun S, Rackoff W. Long-term Survival Advantage for Women Treated With Pegylated Liposomal Doxorubicin Compared With Topotecan in a Phase 3 Randomized Study of Recurrent and Refractory Epithelial Ovarian Cancer. Gynecol Oncol 95:1-8, 2004.

Berek JS, Taylor PT, Gordon A, Cunningham MJ, Finkler N, Orr J, Rivkin S, Schultes BC, Whiteside TL, Nicodemus CF. Randomized Placebo-Controlled Study of Oregovomab for Consolidation of Clinical Remission in Patients with Ovarian Cancer. J Clin Oncol 22:3507-16, 2004.

Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB. SCOTROC 1: Phase III Randomized Trial of Docetaxel-Carboplatin versus Paclitaxel-Carboplatin as First-line Chemotherapy for Ovarian Carcinoma. J NCI 96:1692-91, 2004.

Im SS, Gordon AN, Buttin BM, Leath III CA, Gostout BS, Shah C, Hatch KD, Wang J, Berman ML. Validation of Referral Guidelines for Women with Pelvic Masses. Obstet Gynecol 105:35-41, 2005.

Gordon AN, Finkler N, Edwards RP, Garcia AA, Crozier M, Erwin DH, Barrett E. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a Phase II multicenter study. Int J Gynecol Oncol 15:1-8, 2005.

Seiden MV, Gordon AN, Bodurka DC, Matulonis UA, Penson RT, Alberts DS, Weems G, Cullen, McGuire WP. A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer. Gynecol Oncol 101:55-61, 2006.

Coleman RL, Gordon A, Barter J, Sun S, Rackoff W, Herzog TJ. Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients. Oncologist 12:72-8, 2007.

Mutch DG, Orlando M Goss T, Teneriello MG, Gordon AN, McMeekin SD, Wang Y, Scribner DR, Marciniak, Naumann RW, Secord AA. Randomized phase III trial of gemcitabene compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25:2811-2818, 2007.

Lhomme C, Joly F, Walker JL, Lissoni AA, Nicoletto MO, Manikhas GM, Baekelandt MM, Gordon AN, Fracasso PM, Mietlowski WL, Jones GJ, Dugan MH. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or sup optimally debulked stage III epithelial ovarian cancer. J Clin Oncol 26:2674-2682, 2008.

Chambers SK, Clouser MC, Baker AF, Roe DJ, Cui H, Brewer MA, Hatch KD, Gordon MS, Janicek MF, Isaacs JD, Gordon AN, Nagle RB, Wright HM, Cohen JL, Alberts DS.  Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res 16(21):5320-8, 2010.

Burris HA, Belani CP, Kaufman PA, Gordon AN, Schwartzberg LS, Paroly WS, Shahin S, Dreiling L, Saven A Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies. Oncol Pract 6(3):133-40, 2010.

Gordon AN, Teneriello M, Janicek MF, Hines J, Lim PC, Chen MD, Vaccarello L, Homesley HD, McMeekin S, Burkholder TL, Wang Y, Zhao L, Orlando M, Obasaju CK, Gill JF, Tai DF. Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer. Gynecol Oncol 123(3):479-85, 2011.

Vergote I, Schilder RJ, Pippitt CH Jr, Wong S, Gordon AN, Scudder S, Kridelka F, Dirix L, Leach

JW, Ananda S, Nanayakkara N, Melara R, Bass MB, Litten J, Adewoye H, Wenham RM. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. Gynecol Oncol. 2014 Oct;135(1):25-33. doi: 10.1016/j.ygyno.2014.07.003. Epub 2014 Jul 11. PMID:25019569

Rauh LA, Lachiewicz MP, Gordon AN Ovarian carcinoma initially presenting as breast cancer two years prior to diagnosis: A case report and review of literature.Gynecol Oncol Rep. 2015 Dec 30;15:29-30. doi: 10.1016/j.gore.2015.12.005. eCollection 2016 Jan. PMID:26937485

Alexander VM, Gordon AN, Howard DH, Khanna N. Outcomes and Cost Analysis of Surveillance Strategies After Initial Treatment for Women With Recurrent Ovarian Cancer.

Int J Gynecol Cancer. 2017 Jul 7. doi: 10.1097/IGC.0000000000001040. [Epub ahead of print] PMID: 28692633

Advolodkina P, Lachiewicz MP, Oprea GM, Maimudar B, Gordon AN. Bilateral Fallopian Tube Carcinoma in-situ in a patient with Li-Fraumeni syndrome undergoing hysterectomy for benign indications. What should a gynecologist know about Li-Fraumeni and should we be offering salpingectomy and/or oophorectomy to these patients? Obstet Gynecol (accepted for publication).